Found 11 Ovarian-cancer trials
A listing of Ovarian-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Combination ATR and PARP Inhibitor (CAPRI) trial with AZD6738 and Olaparib in recurrent ovarian cancer
Phase 2
This project studies combination AZD6738 and olaparib (Lymparza) to treat recurrent ovarian cancer. It will examine 1) the safety and tolerability of this drug combination and 2) the overall response rate (tumor strinkage rate) of this therapy. All study patients have recurrent ovarian cancer. None of the patients have standard …
A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)
Phase 2
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability of luveltamab tazevibulin in …
A study of ceralasertib (AZD6738) as monotherapy and in combination with other anticancer agents in patients with advanced solid malignancies Module 5 (ceralasertib in combination with AZD5305) (ANGEL)
Penn Gynecologic Oncology is participating in Module 5 for ovarian cancer patients.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NRG-GY031)
Phase 1
To determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for combination of ATR inhibitor (M1774) and BET inhibitor (ZEN003694) in women with recurrent clear cell, endometrioid, and platinum resistant high grade serous ovarian carcinoma (HGSOC) and clear cell and endometrioid endometrial carcinoma irrespective of ARID1A status.The target …
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Phase 1
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
NRG-CC008: A study to compare two surgical procedures in women with BRCA1 mutations to assess reduced risk of ovarian cancer
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. …
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk- NRG-CC008)
The purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for ovarian …
Study of SynKIR-110 Autologous T cells Transduced with Mesothelin KIR-CAR in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer Cholangiocarcinoma or Mesothelioma (STAR)
Phase 1
This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can …
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (UPROAR)
Phase 2
This study aims to learn more about the use of Mirvetuximab soravtansine and Olaparib as a maintenance therapy after completion of prior therapy for recurrent platinum sensitive ovarian, peritoneal and fallopian tube cancer. Mirvetuximab soravtansine is an effective antibody drug conjugate that targets folate receptor alpha. Olaparib is one of …
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (Xencor)
Phase 2
The purpose of the study is to assess whether an investigational drug, called XmAb20717, has any effects on certain types of cancers and if it is safe and well tolerated.
1 - 10 of 11
- 1
- 2
